KOLOA, Hawaii — Bausch + Lomb has announced that an affiliate of the company has acquired AcuFocus.
The announcement follows FDA approval of AcuFocus’ IC-8 Apthera small-aperture non-toric extended depth of focus IOL in July 2022.
The IC-8 Apthera is indicated for certain cataract patients with low amounts of corneal astigmatism who also wish to address presbyopia at the same time.
“Today’s acquisition of AcuFocus will allow us to further expand upon our IOL portfolio so we can help address the needs of surgeons and their patients with cataracts,” Anthony Wallace,